OBJECTIVES: Chronic kidney disease (CKD) is prevalent in patients undergoing aortic valve replacement (AVR). We sought to evaluate the impact of AVR on estimated glomerular filtration rate (eGFR) levels and determine the impact of reversibility of CKD on postoperative outcomes.
INTRODUCTION
Chronic kidney disease (CKD) is prevalent in patients undergoing aortic valve replacement (AVR) [1] . Long-standing aortic stenosis (AS) and aortic insufficiency (AI) primarily contribute to CKD by impairing forward blood flow from the heart, causing a chronic hypoperfusion state resulting in end-organ damage. Chronic AS can also cause CKD through a late, right-sided heart failure causing venous congestion at the glomerular level whereas chronic AI can cause a late left-sided heart failure due to volume overload, causing further end-organ damage from hypoperfusion [2] . Improvement in cardiac output with AVR should therefore potentially improve renal function by increasing cardiac output and therefore kidney perfusion.
Moreover, this pathological cycle is further perpetuated in patients with end-stage renal disease (ESRD), as progressive, accelerated leaflet calcification is a well-known complication of renal failure [3] .
The dynamic changes in kidney function from the preoperative, perioperative and postoperative phases have not been described, and are not fully understood due to competing effects AVR has on kidney function, i.e. potential to relieve the deleterious renal effects of AS and AI, versus the hazard of ischaemic injury during surgery. The goals of this study were to use estimated glomerular filtration rate (eGFR) to analyse the dynamics of kidney function, as well as to identify predictors of reversibility of CKD, and, finally, to study short-and long-term outcomes following AVR in patients with reversible versus irreversible CKD.
MATERIALS AND METHODS

Patient population
A total of 2169 consecutive patients undergoing AVR at New York Presbyterian Hospital-Columbia University Medical Center between 2000 and 2012 were studied. Demographic and clinical outcomes data were collected from chart review, and analysed retrospectively. All patients met standard indications for surgery for AS or AI. The Institutional Review Board of Columbia University approved all study protocols, and waived informed consent.
Demographics and outcome measures
Baseline characteristics of patients included demographic data, comorbidities, haemodynamic variables, serum laboratory values and need for preoperative haemodialysis.
Renal function was assessed by calculated eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [4] . The CKD-EPI equation, expressed as a single equation, is eGFR ¼ 141 Â min ðCr=k;1Þ a Â max ðCr=k;1Þ À1:209 Â 0:993 Age Â 1:018ðif femaleÞ Â1:159ðif African -AmericanÞ; where Cr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is −0.329 for females and −0.411 for males, min indicates the minimum of Cr/κ or 1 and max indicates the maximum of Cr/κ or 1. The eGFR cutoff points used to delineate patient groups were determined as specified by the National Kidney Disease Foundation Outcomes Quality Initiative (NKF-K/DOQI) guidelines [5] . Based on the preoperative eGFR which was calculated using the closest Cr level within 7 days preoperatively, the study cohort was divided into three groups: normal kidney function (NoCKD, eGFR >60 ml/min/ 1.73 m , n = 47) were excluded as the study focused on reversibility of CKD, which by definition is not applicable to ESRD patients; moreover, most (77%) were on dialysis, and thus had clinically insignificant creatinine and eGFR levels. Preoperative and postoperative characteristics of the three groups were subsequently determined.
The primary outcomes measured were renal function and survival rate at 3, 5 and 10 years. Other outcomes of interest included frequency of major postoperative complications, intensive care unit length of stay (ICULOS), total hospital length of stay (THLOS), discharge status and in-hospital mortality. Renal function was quantified, and followed over time using eGFR with a special focus on reversibility of CKD. Reversibility of CKD was defined as an improvement in eGFR at 1 week postoperatively compared with baseline. Complication and death data were obtained from clinical chart review, and were verified by the national social security as well as the institutional death indexes.
Statistical analysis
Data are represented as frequency distributions and percentages. Continuous variables are presented as mean ± standard deviation and categorical data as percentage and frequency distribution.
Continuous variables were compared using independent sample Student's t-tests, and categorical variables were compared using χ 2 tests with post hoc Fisher's exact test. Paired t-test was used to compare eGFR levels over time. Preoperative characteristics within each CKD group at different follow-up times were compared using independent sample t-testing in order to account for competing risk between the primary outcome and death, as well as ensure homogeneity of patients in the follow-up groups. The Kaplan-Meier estimate was used to depict survival over time. Survival comparisons among groups of patients were completed using Mantel-Haenszel log-rank test.
Predictors of all-time mortality were determined using an adjusted multivariate Cox proportional hazards regression analysis. Adjusted hazard ratios (HRs) were reported for each variable with 95% confidence interval (CI). To determine independent predictors of reversibility of CKD, a multivariable logistic regression was used, adjusted odds ratios and 95% CI were reported. Variables with a P-value less than 0.2 were retained in the regression models. Alpha was set at 0.05 for non-regression analyses. P-values of ≤0.05 were considered statistically significant.
All statistical analyses were performed using SPSS version 21 (IBM Corp., Armonk, NY, USA).
RESULTS
Preoperative and operative characteristics
The baseline characteristics of 2122 patients undergoing AVR are summarized in Table 1 . Mean age of patients was 70.6 ± 14.4 years, and 42.7% were females. Mean follow-up duration was 5.0 ± 5.5 years. The operative variables are summarized in Table 2 . All 2122 cases were isolated AVR, 74% of patients were operated for AS, and 26% for AI. A larger proportion of NoCKD patients had elective surgery (89%) compared with ModCKD and SevCKD patients (respectively 82 and 76%; P < 0.001). Cardiopulmonary bypass (CPB) and cross-clamp (XC) times as well as lowest body temperature on CPB were similar across groups. Patients with NoCKD, ModCKD and SevCKD required increasingly more often intraoperative PRBC transfusions, respectively (23, 47 and 57%, P < 0.001) as well as increasing numbers of PRBC units, respectively (0.6 ± 1.1, 1.2 ± 1.5 and 2.1 ± 3.7 PRBCs, P < 0.001). Valve size was larger in patients with NoCKD compared with ModCKD and SevCKD, respectively (24 ± 3 vs 23 ± 2 and 23 ± 2, P < 0.001). Tissue valves were used in the majority of all patients undergoing surgery.
Postoperative complications
Postoperative complications are summarized in Table 3 . In general, patients with more severe kidney disease had more complicated postoperative hospital courses. Only 4% of patients with NoCKD had respiratory failure (mechanical ventilation >72 h) versus 7% in the ModCKD group and 13% in SevCKD (P < 0.001). Increased ICULOS, THLOS and in-hospital mortality were associated with more severe preoperative CKD, with an ICULOS of 2.4 ± 2.9, 3.4 ± 5.2 and 4.3 ± 4.9 days (P < 0.001), THLOS of 9.8 ± 9.3, 12 ± 10 and 15 ± 11 days and in-hospital mortality of 1, 3 and 4% (P < 0.003), respectively, in the NoCKD, ModCKD and SevCKD groups. There was no difference among groups in terms of other postoperative complications such as reintervention rates, sepsis or sternal wound infection. 
Kidney function and reversibility of chronic kidney disease
The average preoperative eGFR (ml/min/1.73 m 2 ) was 81.3 ± 14.2, 48.9 ± 8.10 and 25.3 ± 4.12 in the NoCKD, ModCKD and SevCKD groups, respectively (P < 0.001). Patients with normal kidney function showed a progressive and slow decline in eGFR up to1 year following AVR, where it reached a value of 74.1 ± 20.2 (P < 0.05 vs baseline) (Fig. 1) . Patients with ModCKD demonstrated an initial improvement in eGFR in the first week postoperatively, at which point a peak of 57.8 ± 19.8 (P < 0.05 vs baseline and vs 2 days) was reached. After 1 week, eGFR decreased slightly and stabilized in ModCKD from 1 week to 1 year to 53.6 ± 19.4, a value still significantly higher than baseline (P < 0.05 vs baseline). eGFR in SevCKD initially increased postoperatively reaching a peak value of 33.6 ± 15.1 at 1 week (P < 0.05 vs baseline); thereafter, it started declining, and reached 30.3 ± 32.2 at 1 month postoperatively a value which was still higher than baseline (P < 0.05 vs baseline). However, owing to limited follow-up beyond 6 months in SevCKD, longer term conclusions concerning dynamics of kidney function cannot be made.
Acute kidney injury (AKI), defined as an increase in Cr >1.5 times or a urine output <0.5 ml/kg/h for >6 h [6] , occurred in 101 (7.1%), 70 (11.3%) and 2 (2.4%) patients in the NoCKD, ModCKD and SevCKD groups, respectively. In the NoCKD group, AKI+ patients had longer ICULOS and THLOS compared with AKI− patients (respectively 3.5 ± 4.6 vs 2.3 ± 2.7 days, P = 0.014 and 13.4 ± 13.2 vs 9.6 ± 8.9 days, P = 0.005). Similarly, in the ModCKD group, AKI+ patients had longer ICULOS and THLOS compared with AKI− patients (respectively 4.5 ± 6.1 vs 3.3 ± 5.0 days, P = 0.107 and 16.1 ± 16.1 vs 11.5 ± 9.3, P = 0.002). Moreover, ModCKD AKI+ patients, suffered more from postoperative sepsis (6 vs 1%, P = 0.004) and were more often re-admitted to the ICU (13 vs 3%, P = 0.001). Finally, in the SevCKD group, the number of events in the AKI+ subgroup was very low; therefore, any statistical analysis would be hard to interpret.
Reversibility of CKD, defined as an improvement in eGFR at 1-week follow-up, was seen in 66% of patients with ModCKD and 69% with SevCKD. By multivariable analysis, factors that were found to be independent predictors of reversibility of renal failure were a younger age [ 
Survival outcomes
In order to ensure no contribution of competing risk of death on the primary outcome of eGFR (i.e. sicker patients with no improvement in eGFR dying and affecting follow-up analysis), independent samples t-test was used to compare patients within each Median survival post AVR was significantly higher in patients with NoCKD versus ModCKD and SevCKD (respectively 4.6 versus 3.5 and 3.1). Importantly, there were significant differences in 1-, 3-, 5-and 10-year survival between patients with SevCKD, ModCKD and NoCKD (log-rank P < 0.001, Fig. 2) . The development of AKI post AVR had an impact on mortality in the ModCKD patients who had higher in-hospital and cumulative mortality rates (respectively 7 vs 2%, P = 0.034 and 43 vs 21%, P < 0.001). The effect of reversibility of CKD on long-term survival was examined in the ModCKD and SevCKD groups (Fig. 3A and B) . Patients with ModCKD who showed improvement in eGFR, had better survival rates at 1-, 3-, 5-and 10-year follow-up when compared with patients with no improvement in eGFR ( Fig. 3A ; log-rank P < 0.001). Patients with reversible SevCKD showed better shortterm survival rates at 1-and 6-month follow-up than patients with irreversible SevCKD (P = 0.018) (Fig. 3B) .
Multivariate Cox regression was performed to identify independent predictors of all-cause mortality related to kidney function, using all pre-, intra-and postoperative risk data and with adjustment for age and gender (Table 5) . Lower baseline eGFR (HR = 0.976, CI 0.962-0.998, P = 0.019), lower preop LVEF (HR = 0.987, CI 0.976-0.998, P = 0.019), COPD (HR = 1.741, CI 1.161-2.611, P = 0.007), age (HR = 1.044, CI 1.022-1.066, P = <0.001), readmission to ICU (HR = 3.733, CI 1.987-7.014, P < 0.001), sepsis (HR = 3.828, CI 1.224-11.937, P = 0.021) and irreversibility of CKD (HR = 1.729, CI 1.247-2.398, P = 0.001) were independent predictive risk factors for mortality in this dataset.
DISCUSSION
The relationship between poor outcomes and CKD in patients following AVR is well established [7, 8] . However, little is known about the reversibility of CKD after relief of AS or AI, the natural history of renal function immediately following AVR in certain CKD subgroups or how reversibility potentially impacts short-and longterm survival. These data are of particular importance given the prominent role that renal dysfunction plays in decision-making between surgical AVR and transcatheter aortic valve replacement (TAVR). In the current study, we examined outcomes following isolated AVR in a large, single-centre experience stratified by levels of CKD defined by updated eGFR definitions and, for the first time, by reversibility of CKD. Our primary findings were as follows: (i) patients with any CKD received higher rates of blood transfusions in the perioperative period, and had longer THLOS, ICULOS and mechanical ventilation duration, (ii) patients with CKD demonstrated a higher in-hospital mortality rate proportional to the severity of CKD compared with patients with no CKD, (iii) patients with moderate CKD experienced significant improvement in eGFR at 1 week to 1 year postoperatively, (iv) predictors of reversibility included younger age, female gender, higher preoperative LVEF, absence of DM, no intraoperative PRBC transfusion, rapid postoperative extubation and no postoperative readmission to the ICU, (v) reversibility of CKD was found to be a negative predictor of all-cause mortality, patients who showed improvement in kidney function at 1-week post AVR had a better survival rate than those with irreversible CKD and (vi) finally, irreversibility of CKD was found to be an independent predictor of long-term mortality. Previous studies have shown similar results to the current study regarding preoperative risk factors, operative courses and longterm survival, and linked severe CKD with worsened outcomes. Gibson et al. [9] found that eGFR is a strong predictor of mortality following AVR with every 10 ml/min/1.73 m 2 decrease corresponding to a 31% increase in postoperative death. A low eGFR (<60 ml/min/1.73 m 2 ) was also found to be the strongest predictor of in-hospital mortality (HR = 5.0, 95% CI 1.87-13.4, P = 0.001) as well as a strong predictor of short-term mortality (HR = 2.98, 95% CI 1.85-4.80, P < 0.001). Similar results have been found analysing the outcomes of 2408 patients undergoing AVR based on the degree of preoperative renal disease, finding the more severe the preoperative renal dysfunction, the lower the long-term survival [10] . Our findings reconfirm these outcomes. Patients with moderate and severe CKD possessed incrementally more severe medical comorbidity, such as reduced LVEF, DM, CVD and COPD. As expected, hospital outcomes were worst for the sickest patients with severe CKD or ESRD, and 1-year survival was 7.2 and 32.3% lower than patients with no CKD, respectively.
Yet, upon further examination of our data, we believe that the presence of comorbidity in patients with CKD should not preclude surgery. In-hospital mortality was only slightly increased in this sick population of patients from 1 to 3% and 4% in no CKD, moderate CKD and severe CKD, respectively; surgery can be safely performed, and excellent outcomes can be expected in patients not yet dependent on dialysis. Moreover, our data strongly suggest that recovery can be expected in patients with ModCKD and even SevCKD, patients groups that stand to benefit the most from renal recovery.
The principle of restoration of cardiac output after relief of outlet obstruction in the case of AS or increase in forward flow in the case of AI, applies broadly to all organ perfusion, but the kidneys may derive the greatest and most immediate benefit from increased perfusion. Here, we show that patients with moderate and severe CKD exhibit a net improvement in eGFR following AVR. Although we are unable to fully explain it, we believe that this recovery of kidney function can be at least partly attributed to both an improved forward flow by the heart and consequently a better end-organ perfusion, and a decrease in venous congestion at the level of the kidneys initially caused by a failing right heart. Reversibility in CKD, defined as an improvement in eGFR sustained at 1 week post-surgery, was associated with an improved short-and mid-term survival in patients with ModCKD and SevCKD, and was found to be an independent negative predictor of long-term mortality (P = 0.001). Reversibility of CKD, if able to be reliably predicted, may provide superior risk stratification compared with serum creatinine alone, which is currently used in standard cardiac surgery risk calculators. Failure to capture which patients will reverse renal dysfunction may grossly overestimate surgical risk.
Little data exist comparing the effect of surgical AVR versus TAVR on renal function. Although not subject to the prolonged haemodynamic fluctuations or inflammatory changes common after surgical AVR or CPB, TAVR affords its own set of risks to the kidney. Exposure to contrast media, brief hypotension from rapid pacing, risk of thromboembolization from catheter manipulation in a calcified aorta and concomitant unaddressed valvular or coronary lesions, may all contribute to renal injury following TAVR. AKI after TAVR poses a serious danger to patients, with over 21% of patients in one series suffering AKI, and serves as a primary determinant of CKD (OR 4.4, P = 0.01) [11] . Surgery versus TAVR has preliminarily been examined in the context of preoperative CKD in 1336 AVR, and 343 TAVR patients [12] . The primary finding was that in-hospital mortality was increased in proportion to worsening GFR in surgical AVR but not TAVR. Neither study examined the changes in eGFR following the procedure, nor randomized patients with CKD to one treatment versus the other. Definitive conclusions regarding the optimal treatment of patients with aortic valve disease with CKD can only be answered with randomization in a clinical trial.
Our study is limited by its retrospective observational nature. Some factors contributing to confounding selection bias might not have been accounted for despite the use of multivariate Cox regression; for example, patients with SevCKD possess significantly more comorbidities than the other groups, and it is impossible to fully eliminate these differences with statistical methods. In addition, with eGFR being a dynamic variable that changes over time and affected by medications or other comorbidities, the use of one preoperative eGFR value to classify the extent of renal failure is not an exact description, but rather an estimate. Regarding eGFR values at follow-up, there is always a risk for changes over time as eGFR is based on Cr values, which in turn, are influenced by physiological and haemodynamic changes. However, although there may be small fluctuations in GFR in the acute setting, we utilize serial changes in GFR at time points distinct enough to reflect true changes in kidney function ( preop, 2 days, 1 week, 1 month etc.). We therefore feel that, though rapid changes occur, the overall trend at these time points should reflect the main concept of the paper, reversibility of kidney function. That being said, we acknowledge that eGFR is a mere estimate of kidney function, an estimate that could be more or less accurate, depending on the acuity of the situation and the rate of change in creatinine values. Concerning the follow-up of kidney function, some main limitations should be mentioned. Firstly, although a longer creatinine and eGFR follow-up would be needed to strengthen the concept of reversibility of kidney failure, a decline in kidney function secondary to ageing could occur, and would thus confound the beneficial effect of AVR. Secondly, in order to fully analyse the factors regulating reversibility of CKD, the aetiology and management of CKD must be analysed; however, this was beyond the scope of this retrospective study. Thirdly, eGFR follow-up was limited to 1 year postoperatively. Although it is a limitation for long-term conclusions, we believe that, in a relatively old population such as the one studied, kidney function beyond 1 year postoperatively is not always a reflection of the postoperative period as many confounders can mask the effect of AVR on the kidneys. Finally, eGFR follow-up numbers beyond 1 year postoperatively were low. However, we show that although a relatively small number of patients were present at follow-up, the patient sample was representative of the baseline cohort as there were no differences in terms of baseline characteristics and comorbidities.
In conclusion, we show for the first time evidence of reversibility of preoperative CKD in patients with moderate and severe CKD following AVR, based on dynamic changes in eGFR following AVR. Reversibility of CKD was associated with improved postoperative outcomes and long-term survival rates. We also demonstrate that preoperative CKD is associated with worsened outcomes after AVR, particularly in patients with no improvement in GFR. This information suggests that reversibility of CKD after AVR is a clinically important concept that may refine risk stratification, facilitate management of CKD in the peri-and postoperative period and potentially even improve survival. More investigation to delineate exact factors contributing to this phenomenon and its clinical use is warranted in patients with severe aortic valve disease.
SUPPLEMENTARY MATERIAL
Supplementary material is available at ICVTS online.
